Yakup Ergün· @dr_yakupergun · X·· 16 小时前评分70
正文 · 原文
#ESMO26 | HARMONi-GI1
Ivonescimab + chemotherapy improving both OS and PFS over the current standard, durvalumab + chemotherapy, in advanced biliary tract cancer is an important result.
If accessible, the new standard of care.
112 浏览 · 1 赞 · 0 转发 · 0 回复
#ESMO26 | HARMONi-GI1| Presidential Session-2 In 1L advanced biliary tract cancer, ivonescimab + chemo vs durvalumab + chemo: 🔹 OS: 14.9 vs 12.1 mo 🔹 PFS: 8.4 vs 5.8 mo 🔹 ORR: 53.8% vs 32.5% A clinically meaningful improvement in OS and PFS against an active SoC comparator在 X 查看被引用的帖子
来源：Yakup Ergün · x.com